- Commercial application of NeuroEEG and NeuroCap growing across ICUs, acute inpatient care and other emergency care in U.S.
- BRSF plans to launch devices in Canada
- Company expands footprint, plans patent applications in Latin America, Europe
Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has unveiled the outlook for 2021. Brain Scientific continues to make strides within neurology by revolutionizing the brain diagnostic market with its groundbreaking technology. The company recently announced that its R&D efforts surged in 2020 with an investment of $275,926, which marks a 266% increase over 2019’s total of $103,616 (https://ibn.fm/Uiqs7).
Despite a challenging year due to the pandemic, Brain Scientific reached significant milestones in 2020. A limited-scope commercial application of the NeuroEEG(TM) and NeuroCap(TM) is in progress in the United States, expected to be followed by the Canadian market. The initial entry market is identified as ICUs, acute inpatient care and other emergency facilities in the United States.
As 2020 drew to a close, Brain Scientific announced that its NeuroCap would become available to the pediatric market in the United States. The child-size NeuroCap headset helps overcome the common challenges medical professionals face when conducting electroencephalograms (“EEG”) in pediatrics by bringing comfort, speed and reliability to the brain testing of children (https://ibn.fm/fWNps).
At the end of last year, the company also filed a patent application for its new long-term monitoring EEG cap. It is a new flexible, full-head EEG cap developed as a response to the market demand for disposable EEG solution for prolonged EEG recordings (12 hours and longer). (https://ibn.fm/Z4Nqv).
Brain Scientific is determined to bring its cutting-edge technology to the world and expand its footprint in the international landscape. Last year, the company established a wholly owned subsidiary in Russia and Europe (Poland) for product distribution and certification, and BRSF appears to have even bigger plans for the future.
Within the next 24 months, the company expects to scale production in the United States, expand into the EU market and file international patent applications in Latin America, Europe and more. Future plans also include the introduction of a BRSF long-term monitoring cap and the addition of long-term monitoring, 24-channel EEG to its proprietary lineup of diagnostic devices.
The third phase of development scheduled for 2021–2022 is also expected to be centered around the use of AI-powered data analysis to bring efficiency, consistency and accuracy to modern neurology diagnostics. This segment is intended to include the launch of data-storage capabilities for normalized data brain scans and the further development of the company’s planned AI neuro net while advancing application for minimally invasive graphene electrodes connected to the micro-EEG. At the forefront of neurology device technology, Brain Scientific appears poised to transform the neurology landscape and establish a new innovative norm for clinicians.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
